Targeted lipid nanoparticles to prevent trans-placental passage in the ex vivo human placental cotyledon perfusion model.
Drug delivery system
Nanomedicine
Placenta (perfusion)
Placenta transport prevention
Pregnancy
Journal
Drug delivery and translational research
ISSN: 2190-3948
Titre abrégé: Drug Deliv Transl Res
Pays: United States
ID NLM: 101540061
Informations de publication
Date de publication:
14 Oct 2024
14 Oct 2024
Historique:
accepted:
19
09
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
14
10
2024
Statut:
aheadofprint
Résumé
Medication use during pregnancy poses risks to both the mother and the fetus. These risks include an elevated potential for fetotoxicity due to placental drug transport. Nanomedicines offer a promising solution by potentially preventing trans-placental passage. Targeted nanomedicines could enhance safety and efficacy in treating maternal or placental pathophysiology. Our study investigates placental transfer kinetics of targeted lipid nanoparticles (LNPs) in an ex vivo human placenta cotyledon perfusion model. We collected human placentas for dual-side ex vivo placental perfusions. Targeted LNPs with a fluorescence tag were introduced into the maternal circuit of each placenta. To establish if there was trans-placental passage of LNPs to the fetal circuit, we collected samples from maternal and fetal circuits throughout the six hours of the perfusion. We determined the fluorescence signal using a multi-mode microplate reader and Multiphoton microscopy to localize the LNPs in the placenta tissue. Data from perfused placenta tissue showed no significant transfer of the fluorescently labeled LNPs across the placental barrier to the fetal circuit. Localization of targeted LNPs in tissue samples is mainly observed in the maternal blood space of the placenta. Our results suggest that targeted LNPs present a promising strategic approach to prevent trans-placental passage to the fetus. Our future perspectives involve investigating the efficacy of targeted LNPs as well as loading targeted LNPs with nucleic acid-based therapeutics to investigate their therapeutic potential.
Identifiants
pubmed: 39402393
doi: 10.1007/s13346-024-01715-6
pii: 10.1007/s13346-024-01715-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : ZonMw
ID : 09120011910045
Pays : Netherlands
Informations de copyright
© 2024. The Author(s).
Références
Keelan JA, Leong JW, Ho D, Iyer KS. Therapeutic and safety considerations of nanoparticle-mediated drug delivery in pregnancy. Nanomedicine. 2015;10:2229–47. https://doi.org/10.2217/nnm.15.48 .
doi: 10.2217/nnm.15.48
pubmed: 26214358
van Kammen CM, van Woudenberg SJ, Schiffelers R, Terstappen F, Lely AT. Nanomedicines: An approach to treat placental insufficiency and the current challenges, J Control Release, vol. 360, pp. 57–68, Aug. 2023, https://doi.org/10.1016/J.JCONREL.2023.06.003
Cureton N, et al. Selective targeting of a novel vasodilator to the uterine vasculature to treat impaired uteroplacental perfusion in pregnancy. Theranostics. 2017;7(15):3715–31. https://doi.org/10.7150/thno.19678 .
doi: 10.7150/thno.19678
pubmed: 29109771
pmcid: 5667343
Alfaifi AA et al. Megalin-targeting liposomes for placental drug delivery, https://doi.org/10.1016/j.jconrel.2020.05.033
King A, et al. Tumor-homing peptides as tools for targeted delivery of payloads to the placenta. Sci Adv. 2016;2:1–16. https://doi.org/10.1126/sciadv.1600349 .
doi: 10.1126/sciadv.1600349
Zhang B, et al. Placenta-specific drug delivery by trophoblast-targeted nanoparticles in mice. Theranostics. 2018;8(10):2765–81. https://doi.org/10.7150/thno.22904 .
doi: 10.7150/thno.22904
pubmed: 29774074
pmcid: 5957008
Ickenstein LM, Garidel P. Lipid-based nanoparticle formulations for small molecules and RNA drugs, Expert Opin Drug Deliv, vol. 16, no. 11, pp. 1205–1226, Nov. 2019, https://doi.org/10.1080/17425247.2019.1669558
Turanov AA et al. Dec., RNAi Modulation of Placental sFLT1 for the Treatment of Preeclampsia., Nat Biotechnol, vol. 36, no. 12, pp. 1164–1173, 2018, https://doi.org/10.1038/NBT.4297
Tang H, Gao Y, Han J. Application progress of the single domain antibody in Medicine. Int J Mol Sci. Feb. 2023;24(4). https://doi.org/10.3390/IJMS24044176 .
Swart LE, et al. Increased bone marrow uptake and Accumulation of very-late Antigen-4 targeted lipid nanoparticles. Pharmaceutics. May 2023;15(6). https://doi.org/10.3390/pharmaceutics15061603 .
Li L, Li H, Xue J, Chen P, Zhou Q, Zhang C. Nanoparticle-Mediated Simultaneous Downregulation of Placental Nrf2 and sFlt1 Improves Maternal and Fetal Outcomes in a Preeclampsia Mouse Model, ACS Biomater Sci Eng, vol. 6, no. 10, pp. 5866–5873, Oct. 2020, https://doi.org/10.1021/acsbiomaterials.0c00826
Li L, et al. Trophoblast-targeted Nanomedicine modulates placental sFLT1 for Preeclampsia Treatment. Front Bioeng Biotechnol. Feb. 2020;8. https://doi.org/10.3389/FBIOE.2020.00064 .
Davis SM, et al. Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1. Mol Ther Nucleic Acids. Sep. 2022;29:135–49. https://doi.org/10.1016/J.OMTN.2022.06.009 .
Grigsby PL. Animal models to study placental development and function throughout normal and dysfunctional human pregnancy. Semin Reprod Med. Jan. 2016;34(1):11–6. https://doi.org/10.1055/S-0035-1570031 .
Aengenheister L, et al. Research on nanoparticles in human perfused placenta: state of the art and perspectives. Placenta. 2021;104:199–207. https://doi.org/10.1016/j.placenta.2020.12.014 .
doi: 10.1016/j.placenta.2020.12.014
pubmed: 33418345
van Moorsel MVA, et al. A head-to-head comparison of conjugation methods for VHHs: Random maleimide-thiol coupling versus controlled click chemistry. Int J Pharm X. Dec. 2019;1. https://doi.org/10.1016/J.IJPX.2019.100020 .
Danaei M et al. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems, Pharmaceutics 2018, Vol. 10, Page 57, vol. 10, no. 2, p. 57, May 2018, https://doi.org/10.3390/PHARMACEUTICS10020057
Lackman F, Capewell V, Gagnon R, Richardson B. Fetal umbilical cord oxygen values and birth to placental weight ratio in relation to size at birth. Am J Obstet Gynecol. 2001;185(3):674–82. https://doi.org/10.1067/MOB.2001.116686 .
doi: 10.1067/MOB.2001.116686
pubmed: 11568797
Hayward CE et al. Feb., Placental Adaptation: What Can We Learn from Birthweight:Placental Weight Ratio? Front Physiol, vol. 7, no. FEB, 2016, https://doi.org/10.3389/FPHYS.2016.00028
Schneider H, Panigel M, Dancis J. Transfer across the perfused human placenta of antipyrine, sodium and leucine. Am J Obstet Gynecol. Nov. 1972;114(6):822–8. https://doi.org/10.1016/0002-9378(72)90909-X .
Schneider H, Huch A. Dual in vitro perfusion of an isolated lobe of human placenta: method and instrumentation., Contrib Gynecol Obstet. 1985;13:40–47., vol. 13, pp. 40–47, 1985.
Bukkems VE et al. Aug., Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments, Clin Pharmacokinet, vol. 61, no. 8, pp. 1129–1141, 2022, https://doi.org/10.1007/S40262-022-01127-0
Lang F, et al. Functional significance of cell volume regulatory mechanisms. Physiol Rev. 1998;78(1):247–306. https://doi.org/10.1152/PHYSREV.1998.78.1.247 .
doi: 10.1152/PHYSREV.1998.78.1.247
pubmed: 9457175
Vergnes J-N. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, New England Journal of Medicine, vol. 384, no. 16, pp. 1576–1578, Apr. 2021, https://doi.org/10.1056/nejmc2036242
Baden LR et al. Feb., Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine, N Engl J Med, vol. 384, no. 5, pp. 403–416, 2021, https://doi.org/10.1056/NEJMOA2035389
Omo-Lamai S, et al. Lipid nanoparticle-Associated inflammation is triggered by sensing of endosomal damage: Engineering endosomal escape without Side effects. bioRxiv Apr. 2024. https://doi.org/10.1101/2024.04.16.589801 .
doi: 10.1101/2024.04.16.589801
Sharma P, Hoorn D, Aitha A, Breier D, Peer D. The immunostimulatory nature of mRNA lipid nanoparticles. Adv Drug Deliv Rev. Feb. 2024;205. https://doi.org/10.1016/J.ADDR.2023.115175 .
Moghimi SM, Simberg D. Pro-inflammatory concerns with lipid nanoparticles. Mol Ther. Jun. 2022;30(6):2109–10. https://doi.org/10.1016/J.YMTHE.2022.04.011 .
Eliesen GAM et al. Jul., Assessment of Placental Disposition of Infliximab and Etanercept in Women With Autoimmune Diseases and in the Ex Vivo Perfused Placenta, Clin Pharmacol Ther, vol. 108, no. 1, pp. 99–106, 2020, https://doi.org/10.1002/CPT.1827
Wilson RL, et al. Nanoparticle mediated increased insulin-like growth factor 1 expression enhances human placenta syncytium function. Placenta. Apr. 2020;93:1–7. https://doi.org/10.1016/J.PLACENTA.2020.02.006 .
Anupa R, Menjoge, et al. Transfer of PAMAM dendrimers across human placenta: prospects of its use as drug carrier during pregnancy. Bone. 2008;23(1):1–7.
Grafmueller S, et al. Bidirectional transfer study of polystyrene nanoparticles across the placental barrier in an ex vivo human placental perfusion model. Environ Health Perspect. 2015;123(12):1280–6. https://doi.org/10.1289/ehp.1409271 .
doi: 10.1289/ehp.1409271
pubmed: 25956008
pmcid: 4671239
Hermans S, et al. Definition and quantification of three-dimensional imaging targets to phenotype Pre-eclampsia subtypes: an exploratory study. Int J Mol Sci. Feb. 2023;24(4). https://doi.org/10.3390/IJMS24043240 .
Yang H, et al. Effects of gestational age and surface modification on materno-fetal transfer of nanoparticles in murine pregnancy. Sci Rep. 2012;2. https://doi.org/10.1038/SREP00847 .
Jauniaux E, Gulbis B. In vivo investigation of placental transfer early in human pregnancy. Eur J Obstet Gynecol Reproductive Biology. 2000;92(1):45–9. https://doi.org/10.1016/S0301-2115(00)00424-3 .
doi: 10.1016/S0301-2115(00)00424-3
Vangrieken P, et al. Placental hypoxia-induced alterations in vascular function, morphology, and endothelial barrier integrity. Hypertens Res. Dec. 2020;43(12):1361–74. https://doi.org/10.1038/S41440-020-0528-8 .
Wang Y, Lewis DF, Gu Y, Zhang Y, Alexander JS, Granger DN. Placental trophoblast-derived factors diminish endothelial barrier function. J Clin Endocrinol Metab. May 2004;89(5):2421–8. https://doi.org/10.1210/JC.2003-031707 .